Glaukos touts 3-year iStent data

Glaukos (NYSE:GKOS) today released 3-year results from a study of its iStent trabecular micro-bypass stents, touting a 43% reduction in mean intraocular pressure in glaucoma patients treated with the device. Results were published in the journal Ophthalmology and Therapy this month, the Laguna Hills, Calif.-based company said. Glaukos’ iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. Data in the prospective study came from 101 patients with primary open-angle glaucoma at a single investigational site, who received either 2 iStents or topical travoprost. Results indicated a mean IOP reduction of 43% for patients treated with the iStent, reduced from 25.5 mm Hg to 14.6 mm Hg. Data from the travoprost arm indicated a 39% reduction in IOP, moving from 25.1 mm Hg to 15.3 mm Hg. A total 23% of the patients treated with travoprost required additional topical medication therapy, compared with 11% of patients treated with iStent, according to the study. Mean intraocular pressure was reported at 18 mm Hg or below for 91% of the patients in the stent group without the need for additional topical meds, and 79% for patients in the travoprost group. “We embarked on this study to assess the potential utility of iStent as an initial treatment in naïve open-angle glaucoma patients versus topical travopr...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news